This is concerning because the existing data only suggest that FTO expression influences the sensitivity of patients with ovarian cancer to chemotherapy, and further evidence from randomized controlled trials offering a higher level of evidence is necessary to substantiate this conclusion (Table 4). The gene discussed is FTO; the disease is ovarian carcinoma.